Crossmark

Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single‐center experience

Published Online: 2019-10-16

Published Print: 2019-12

Authors

Peng, Jianhong

Li, Weihao

Zhang, Rongxin

Lin, Junzhong

Tang, Jinghua

Wen, Yongshan

Lu, Zhenhai

Wu, Xiaojun

Pan, Zhizhong https://orcid.org/0000-0002-5198-2919
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81772595)
License Information

Version of Record valid from 2019-10-16
More Information

Publication History

Received: 2019-05-13

Accepted: 2019-09-20

Published: 2019-10-16

Document is current